-+ 0.00%
-+ 0.00%
-+ 0.00%

Alpha Tau Medical Announces FDA Approval Of Investigational Device Exemption Supplement To Its U.S. IMPACT Trial Evaluating Alpha DaRT To Treat Unresectable Locally Advanced Or Metastatic Pancreatic Adenocarcinoma

Benzinga·04/23/2026 13:09:42
Listen to the news

Alpha Tau Medical Ltd. (NASDAQ:DRTS, DRTSW)) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® today announced that the FDA has approved an Investigational Device Exemption (IDE) supplement to its U.S. multi-center pancreatic cancer pilot study, known as IMPACT (Intratumoral Pancreatic Alpha Combination Trial), evaluating the safety, feasibility, and efficacy of Alpha DaRT in combination with chemotherapy for patients with newly diagnosed unresectable locally advanced or metastatic pancreatic adenocarcinoma.